BLS Pharmaceuticals Limited (ASX:BLS)
Australia · Delayed Price · Currency is AUD 1.180
-0.025 (-2.07%)
Sep 22, 2026, 4:10 PM AEST
BLS Pharmaceuticals Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 13.29 | 7.67 | 1.03 | 3.85 | 0.07 |
Cash & Short-Term Investments | 13.29 | 7.67 | 1.03 | 3.85 | 0.07 |
Cash Growth | 73.32% | 645.88% | -73.27% | 5733.24% | -95.88% |
Accounts Receivable | 7.65 | 2.35 | 0.98 | 0.83 | 0.23 |
Other Receivables | 0.33 | 0.18 | 0.26 | 0.18 | 0.02 |
Receivables | 7.98 | 2.54 | 1.24 | 1.01 | 0.25 |
Inventory | 17.82 | 3.61 | 2.14 | 0.99 | 0.08 |
Prepaid Expenses | 2.12 | 0.87 | 0.76 | 0.19 | 0.01 |
Other Current Assets | - | 1.06 | 0.42 | 0 | 0 |
Total Current Assets | 41.21 | 15.74 | 5.59 | 6.04 | 0.4 |
Property, Plant & Equipment | 10.06 | 3.37 | 0.82 | 0.09 | 0.04 |
Goodwill | - | - | - | 11.57 | - |
Other Intangible Assets | 0.11 | - | - | - | - |
Long-Term Deferred Tax Assets | 0.26 | - | - | - | - |
Long-Term Deferred Charges | 0.28 | 0.39 | 0.29 | - | - |
Other Long-Term Assets | 0.17 | 0.08 | - | - | - |
Total Assets | 52.08 | 19.58 | 6.7 | 17.69 | 0.45 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 7.13 | 2.73 | 1.19 | 1.21 | 0.2 |
Accrued Expenses | 2.26 | 1.4 | 0.87 | 0.69 | 0.11 |
Short-Term Debt | 0.45 | - | 0.04 | 0.56 | 0.4 |
Current Portion of Long-Term Debt | 0.64 | 0.07 | - | - | - |
Current Portion of Leases | 0.56 | 0.4 | 0.18 | - | - |
Current Income Taxes Payable | 0.02 | - | - | - | - |
Current Unearned Revenue | 2.66 | 1.06 | - | - | - |
Other Current Liabilities | 0.49 | 0.74 | 0.62 | 0.23 | 0.1 |
Total Current Liabilities | 14.22 | 6.4 | 2.91 | 2.69 | 0.82 |
Long-Term Debt | 1.93 | 0.28 | - | - | - |
Long-Term Leases | 4.85 | 0.79 | 0.49 | - | - |
Other Long-Term Liabilities | - | - | - | - | -0 |
Total Liabilities | 21 | 7.47 | 3.4 | 2.69 | 0.81 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 24.6 | 21.48 | 19 | 17.55 | 0.13 |
Retained Earnings | 4.39 | -10.7 | -15.6 | -2.48 | -0.54 |
Comprehensive Income & Other | 2.1 | 1.63 | 0.21 | 0.07 | 0.05 |
Total Common Equity | 31.09 | 12.41 | 3.61 | 15.14 | -0.36 |
Minority Interest | - | -0.31 | -0.31 | -0.13 | - |
Shareholders' Equity | 31.09 | 12.1 | 3.3 | 15.01 | -0.36 |
Total Liabilities & Equity | 52.08 | 19.58 | 6.7 | 17.69 | 0.45 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 8.43 | 1.53 | 0.71 | 0.56 | 0.4 |
Net Cash (Debt) | 4.86 | 6.13 | 0.32 | 3.29 | -0.33 |
Net Cash Growth | -20.84% | 1831.58% | -90.34% | - | - |
Net Cash Per Share | 0.02 | 0.03 | 0.00 | 0.02 | -0.00 |
Filing Date Shares Outstanding | 230.3 | 217.18 | 204.66 | 190.16 | 64.01 |
Total Common Shares Outstanding | 229.98 | 216.48 | 204.66 | 190.16 | 64.01 |
Working Capital | 26.99 | 9.34 | 2.68 | 3.35 | -0.41 |
Book Value Per Share | 0.14 | 0.06 | 0.02 | 0.08 | -0.01 |
Tangible Book Value | 30.98 | 12.41 | 3.61 | 3.57 | -0.36 |
Tangible Book Value Per Share | 0.13 | 0.06 | 0.02 | 0.02 | -0.01 |
Machinery | 3.37 | 2.19 | 0.38 | - | 0.08 |
Construction In Progress | 1.63 | - | - | - | - |
Leasehold Improvements | 1.12 | 0.61 | - | - | - |